Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNT-517 in Adolescent Participants With Phenylketonuria
NCT06637514Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of repinatrabit in phenylketonuria (PKU) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Number of participants with treatment-emergent adverse events at 9 weeks. Started Jul 2025; status: completed.
02
Drugs
repinatrabit
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT06637514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637514.